Cecilia BrownMyeloma | July 3, 2023
The trial compared ciltacabtagene autoleucel with standard of care in patients with MM who were refractory to lenalidomide.
Read More
Cecilia BrownAcute Myeloid Leukemia | June 23, 2023
The researchers used a 3+3 study design to determine the maximum tolerated dose of CC-486 plus venetoclax.
Cecilia BrownAcute Myeloid Leukemia | June 21, 2023
SAR’579 targets CD123 and co-engages NKp46 and CD16a on natural killer cells.
Chadi Nabhan, MD, MBA, FACPMeeting News | June 14, 2023
Dr. Nabhan, who hosts The HemOnc Pulse, discusses the podcast and what he hopes listeners gain from it at ASCO 2023.
Cecilia BrownMeeting News | July 19, 2023
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Chadi Nabhan, MD, MBA, FACPVideo Insights | June 14, 2023
Dr. Nabhan also speaks about his next book, which is expected to be released in fall 2024.
Leah SherwoodMeeting News | June 12, 2023
The retrospective review was conducted by abstracting data from the medical charts of patients with Burkitt lymphoma.
Leah SherwoodMeeting News | February 8, 2024
Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive ATL who were not candidates for allogeneic HSCT.
Cecilia BrownMeeting News | June 9, 2023
Less than half of patients had “clinically significant” CMV reactivation that required antiviral therapy.
Cecilia BrownMeeting News | June 9, 2023
With four years of follow-up data, the best complete response rate was 58%.
Cecilia BrownMyeloproliferative Neoplasms | June 8, 2023
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
Cecilia BrownMeeting News | June 12, 2023
The study included patients who underwent an evaluation for allogeneic HSCT at a large academic medical center.
Cecilia BrownMeeting News | June 7, 2023
The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks.
Cecilia BrownChronic Lymphocytic Leukemia | June 6, 2023
Jennifer Woyach, MD and colleagues presented the study's results during the 2023 ASCO Annual Meeting.
Cecilia BrownMyelodysplastic Syndromes | June 8, 2023
Most patients (82%) had a low transfusion burden at baseline.
Cecilia BrownMeeting News | June 8, 2023
Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting.
Cecilia BrownMyelodysplastic Syndromes | June 8, 2023
A subset of TP53-mutated myeloid neoplasms, such as MDS, are preceded by TP53-mutated CCUS.
Cecilia BrownMyelodysplastic Syndromes | June 5, 2023
Nearly one-third (29%) of patients were upstaged from their IPSS-R score by the IPSS-M.
Cecilia BrownMyelodysplastic Syndromes | February 8, 2024
Dr. Garcia-Manero presented information about a phase Ib study of IRAK1/4 inhibition at the 2023 ASCO Annual Meeting.
Cecilia BrownIndolent B-Cell Lymphoma | February 8, 2024
Pola-R-CHP and R-CHOP “demonstrated similar safety profiles” in older adults with previously untreated DLBCL.
Editorial Board